title: Management of Hormone Deprivation Symptoms After Cancer.
abstract: Cancer survivors often experience symptoms related to hormone deprivation, including vasomotor symptoms, genitourinary symptoms, and sexual health concerns. These symptoms can occur due to natural menopause in midlife women, or they can be brought on by oncologic therapies in younger women or men. We searched PubMed for English-language studies from January 1990 through January 2016 to identify relevant articles on the management of hormone deprivation symptoms, including vasomotor, genitourinary, and sexual symptoms in patients with cancer. The search terms used included hormone deprivation, vasomotor symptoms, hot flash, vaginal dryness, sexual dysfunction, and breast cancer. This manuscript provides a comprehensive description of data supporting the treatment of symptoms associated with hormone deprivation.
authors: Women's Health Clinic, Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN. Electronic address: Faubion.Stephanie@mayo.edu.
authors: Stephanie S
authors: SS
authors: Faubion
authors: Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN.
authors: Charles L
authors: CL
authors: Loprinzi
authors: Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN.
authors: Kathryn J
authors: KJ
authors: Ruddy
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D052776:Female Urogenital Diseases / Q000139:chemically induced* / Q000628:therapy; D012739:Gonadal Steroid Hormones / Q000172:deficiency*; D020249:Hormone Replacement Therapy / Q000009:adverse effects* / Q000592:standards; D019584:Hot Flashes / Q000209:etiology / Q000628:therapy; D006801:Humans; D008297:Male; D052801:Male Urogenital Diseases / Q000139:chemically induced* / Q000628:therapy; D009369:Neoplasms / Q000150:complications* / Q000178:diet therapy; D011374:Progesterone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced* / Q000628:therapy; D017741:Survivors; D014666:Vasomotor System / Q000187:drug effects* / Q000503:physiopathology
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D000970:Antineoplastic Agents; D018680:Cholinergic Antagonists; D004967:Estrogens; D012739:Gonadal Steroid Hormones; D011374:Progesterone